Photo: poba/GettyImages
Verily announced a multi-year strategic collaboration with UCHealth, the University of Colorado Anschutz and RefinedScience to alter how data is used and care is delivered.
Based in Colorado, CU Anschutz and UCHealth will collect biomedical data on the Verily platform, creating AI-ready, research-grade biomedical data pipelines and developing novel AI/ML models across vital therapeutic areas such as oncology, cardiovascular, musculoskeletal, neuroscience, ophthalmology and transplant medicine.
Through pre-processing of disparate, multi-modal data, Verily's platform enables advanced analytics and the deployment of AI models that can help life science and pharma companies reduce the time to market for critical therapies while permitting health systems and payers to improve outcomes at lower costs.
Additionally, CU Anschutz researchers will work together using Verily's research environment, Verily Workbench, which enables secure and scalable handling of data within robust governance and consent frameworks.
Meanwhile, Verily and RefinedScience will explore emerging cutting-edge tools and techniques for evaluating intricate biological data.
UCHealth, the University of Colorado Anschutz and RefinedScience also plan to leverage the full range of Verily’s product portfolio, speed up system-wide technology strategies, co-develop next-generation capabilities and broaden revenue streams.
"We are proud to collaborate with UCHealth, the University of Colorado Anschutz and RefinedScience and share their vision for using technology to advance best-in-class care for patients," Stephen Gillett, CEO of Verily, said in a statement.
"Our platform and solutions are designed to transform complex, unstructured healthcare data into organized, actionable insights, enabling our customers and collaborators to accelerate scientific discovery and improve care for patients and their communities."
THE LARGER TREND
In June, Verily announced that it would continue its partnership with Vanderbilt University Medical Center to support the National Institutes of Health (NIH) All of Us Research Program’s Researcher Workbench platform.
The Researcher Workbench gives help to more than 17,000 registered researchers from all 50 states and over 1,100 organizations worldwide.
It supports more than 18,000 active biomedical research studies.
The expanded collaboration continued Verily's work alongside VUMC and other partners to provide researchers with safe, cloud-based access to examine biomedical data via the Researcher Workbench platform.
In May, Verily was awarded a $14.7 million research grant from Michael J. Fox Foundation for Parkinson's research to generate a detailed molecular dataset of Parkinson's disease.
The initiative integrated advanced molecular profiling with an extensive body of clinical, imaging and wearable data collected via the Personalized Parkinson's Project (PPP).
The PPP is a two-year longitudinal study conducted in conjunction with Radboud University Medical Center. It involved 520 individuals diagnosed with Parkinson's.
The study captured multimodal datasets, including biospecimens, clinical histories, imaging scans and physiological data.
In April, Verily added several new institutions using Workbench to manage its large biomedical datasets, as it introduces new features.
They included: NashBio, University of Oxford and NIH Intramural Center for Alzheimer’s and Related Dementias.
In 2024, Andrew Trister, Verily's chief medical and science officer, sat down with MobiHealthNews to talk about the company's use of AI technology, its work with tech giant Google and what excites him about the business's future.
